Pharmacologic and Supportive Therapies for Acute Spinal Cord Injury Disability: A Registry-Based Clinical Trial Analysis

Spinal cord injury (SCI) is a catastrophic neurological emergency and a leading cause of permanent physical disability worldwide. Beyond the immediate life-threatening phase, SCI results in long-term motor, sensory, and autonomic impairments that substantially affect independence, participation, and quality of life. Early management is critical because therapeutic interventions implemented during the emergency and acute phases can influence both survival and long-term disability outcomes. This study analyzed completed interventional clinical trials investigating therapies for SCI in emergency or acute care settings, with a particular focus on interventions targeting disability-related complications. A descriptive analysis of completed interventional clinical trials registered on ClinicalTrials.gov was conducted, with data retrieval and extraction completed on 17 June 2025. Trials were evaluated according to intervention type, disability-related clinical targets, primary outcome measures, enrollment size, and study design characteristics. A total of 15 completed interventional trials were identified. The studies evaluated a range of therapeutic approaches, including gabapentin, botulinum toxin A, neostigmine, lidocaine, and Microcyn, targeting conditions such as neuropathic pain, bowel dysfunction, autonomic instability, and pressure ulcers. Most studies employed randomized designs, with enrollment sizes ranging from 13 to 360 participants. Outcome measures varied considerably and included pain assessment scales, cardiovascular responses, bowel function parameters, and wound-healing metrics. Overall, current emergency-phase therapeutic research in SCI primarily focuses on managing disability-related complications rather than promoting neurological restoration. Although these interventions are important for reducing secondary disability and preserving function, the available evidence remains limited by small sample sizes and heterogeneous outcome measures. Future large-scale, multicenter clinical trials with standardized outcome reporting are needed to strengthen the evidence base for acute SCI management and improve long-term functional outcomes.